Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 42 out of 100. How common it is

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

In 2021, Asia experienced a 250.44% increase in prevalent cases, a 297.34% rise in mortality, and a 249.54% surge in DALYs for AD and other dementias compared to 1990. Meanwhile, the age-standardized prevalence rate, age-standardized mortality rate, and age-standardized DALY rate also exhibited varying degrees of rise from 1990 to 2021. Demographically, the disease burden was higher in women and those aged 65 and above. Regionally, the burden was highest in East Asia and relatively low in South and Central Asia. Nationally, China, India, Japan, and Indonesia reported the most cases. Over the next 15 years, the age-standardized prevalence rate in Asia is expected to peak in 2028 before declining, while the age-standardized mortality rate is anticipated to keep rising. An overall "V" shaped association was found between sociodemographic index (SDI) and the age-standardized DALY rate in Asia. Only smoking, high fasting plasma glucose (FPG), and high BMI were identified as causal risk factors within the GBD framework. The burden of AD and other dementias in Asia has significantly increased over the past three decades and is expected to persistently impact Asian populations, particularly in developing countries experiencing rapid demographic shifts. Women and the older adult should be a focus of attention. It is imperative to implement targeted prevention and intervention strategies, enhance chronic disease management, and control risk factors.

What this study adds

Evidence grade: Low

This analysis describes large increases in dementia cases, deaths, and disability across Asia since 1990, with the burden highest in women, people 65 and older, and East Asia. Reported effect size: 250.44%; 297.34%; 249.54%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

He, Z., Zhang, H., Hu, G., Qiao, Y., Yin, C., Li, J., et al. (2025). The current status, trends, and challenges of Alzheimer’s disease and other dementias in Asia (1990–2036). Frontiers in Public Health. https://doi.org/10.3389/fpubh.2025.1583339

Vancouver

He Z, Zhang H, Hu G, Qiao Y, Yin C, Li J, et al. The current status, trends, and challenges of Alzheimer’s disease and other dementias in Asia (1990–2036). Frontiers in Public Health. 2025. doi:10.3389/fpubh.2025.1583339. PMID: 40556904.

BibTeX

@article{he2025-40556904,
  author  = {He, Ziyang and Zhang, Haoqin and Hu, Guishan and Qiao, Yinan and Yin, Can and Li, Jianqiao and Lin, Hong and others},
  title   = {{The current status, trends, and challenges of Alzheimer’s disease and other dementias in Asia (1990–2036)}},
  journal = {Frontiers in Public Health},
  year    = {2025},
  doi     = {10.3389/fpubh.2025.1583339},
  pmid    = {40556904},
  url     = {https://doi.org/10.3389/fpubh.2025.1583339}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This analysis describes large increases in dementia cases, deaths, and disability across Asia since 1990, with the burden highest in women, people 65 and older, and East Asia. It identifies smoking, high fasting plasma glucose, and high BMI as risk factors but tests no treatment, cure, or prevention.

Study details

How this study scored 42/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 0 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 42 of 100.42 of 100 points earned58 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in Public Health)
Journal's citation record 2 / 4 Frontiers in Public Health: journal h-index 174 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 20 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 6.7 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 12.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 0 / 4 Last-listed author Lu Yu: h-index 3 (OpenAlex, whole career)
Institution's track record 0 / 3 Macau University of Science and Technology: institution h-index 292 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40556904)
Free to read 2 / 2 Free to read
Total 42 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in How common it is from nearby years

Also in How common it is

80 studies in the library are filed under How common it is with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The How common it is hub.

Similar studies

More on How common it is

See all studies in How common it is →